As our sequencing analysis of advanced HER2 + breast tumors identified recurrent mutations in multiple MAPK pathway members (Fig. 1a), we asked whether pathway activation through mutational mechanisms other than NF1 loss also promotes resistance to HER2i. Here, ERBB2 is linked to breast neoplasm.